VERTEX PHARMACEUTICALS INC / MA VRTX
Pharmaceutical Preparations · Nasdaq
Revenue
$9.87B
+10.5% YoY
Net income
$3.62B
+9.0% YoY
Total assets
$22.53B
-0.9% YoY
EPS
13.89
+8.3% YoY
Advertisement
Income Statement
| Period | 2026 Q2 | 2026 Q1 | 2025 FY | 2025 Q3 | 2025 Q2 | 2025 Q1 | 2024 FY | 2024 Q3 |
|---|---|---|---|---|---|---|---|---|
| Revenues | $5.73B | $2.77B | $9.87B | $8.11B | $5.34B | $2.69B | $8.93B | $7.35B |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| R&D Expense | — | — | — | — | — | — | — | — |
| SG&A Expense | $821.00M | $396.40M | $1.14B | $1.09B | $714.90M | $342.70M | $944.70M | $767.50M |
| Operating Income (Loss) | $1.78B | $630.10M | $3.83B | $-1.26B | $-2.38B | $1.14B | $4.31B | $2.84B |
| Interest Expense | — | — | — | — | — | — | — | — |
| Net Income (Loss) | $1.68B | $646.30M | $3.62B | $-1.45B | $-2.49B | $1.10B | $3.32B | $2.65B |
| EPS (Diluted) | 6.48 | 2.49 | 13.89 | -5.61 | -9.66 | 4.21 | 12.82 | 10.18 |
Balance Sheet
| Period | 2026 Q2 | 2026 Q1 | 2025 FY | 2025 Q3 | 2025 Q2 | 2025 Q1 | 2024 FY | 2024 Q3 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $25.64B | $25.64B | $22.53B | $22.53B | $22.53B | $22.53B | $22.73B | $22.73B |
| Current Assets | $11.20B | $11.20B | $9.60B | $9.60B | $9.60B | $9.60B | $14.14B | $14.14B |
| Cash & Equivalents | $4.57B | $4.57B | $10.50B | $10.37B | $10.37B | $10.37B | $6.79B | $10.50B |
| Accounts Receivable | $2.05B | $2.05B | $1.61B | $1.61B | $1.61B | $1.61B | $1.56B | $1.56B |
| Inventory | $1.69B | $1.69B | $1.21B | $1.21B | $1.21B | $1.21B | $738.80M | $738.80M |
| PP&E (Net) | — | — | — | — | — | — | — | — |
| Goodwill | $1.09B | $1.09B | $1.09B | $1.09B | $1.09B | $1.09B | $1.09B | $1.09B |
| Total Liabilities | $6.98B | $6.98B | $6.12B | $6.12B | $6.12B | $6.12B | $5.15B | $5.15B |
| Current Liabilities | $3.86B | $3.86B | $3.56B | $3.56B | $3.56B | $3.56B | $3.55B | $3.55B |
| Accounts Payable | $461.70M | $461.70M | $413.00M | $413.00M | $413.00M | $413.00M | $364.90M | $364.90M |
| Long-Term Debt | — | — | — | — | — | — | — | — |
| Stockholders Equity | $16.41B | $16.41B | $13.91B | $17.58B | $17.58B | $17.58B | $10.10B | $13.91B |
Cash Flow Statement
| Period | 2026 Q2 | 2026 Q1 | 2025 FY | 2025 Q3 | 2025 Q2 | 2025 Q1 | 2024 FY | 2024 Q3 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $1.89B | $818.90M | $3.54B | $-1.08B | $-2.45B | $1.31B | $4.13B | $3.30B |
| Investing Cash Flow | $-540.30M | $-55.80M | $-3.14B | $-2.95B | $-2.60B | $-2.14B | $-321.10M | $-2.26B |
| Financing Cash Flow | $-1.03B | $-680.40M | $-562.20M | $-1.10B | $-716.10M | $-357.50M | $-67.70M | $-442.40M |
| Stock Repurchases | $817.90M | $426.10M | $427.60M | $759.20M | $451.50M | $131.20M | $0 | $278.10M |
Similar companies
AbbVie Inc.
ABBV
ABBOTT LABORATORIES
ABT
BRISTOL MYERS SQUIBB CO
BMY
JOHNSON & JOHNSON
JNJ
ELI LILLY & Co
LLY
Merck & Co., Inc.
MRK
PFIZER INC
PFE
REGENERON PHARMACEUTICALS, INC.
REGN
Learn more
How to Find Any SEC Filing in Two MinutesCash-Flow Quality: Profit Is an Opinion, Cash Is a FactValuation Basics: P/E, P/S and What They Actually Tell YouDividends: How Companies Pay Shareholders and How to Read ThemHow to Read a 10-K Annual Report (Without Falling Asleep)Understanding Earnings Per Share (EPS)How to Read a Cash Flow StatementHow to Read a Balance SheetHow to Read an Income Statement
Data is sourced from the U.S. SEC EDGAR public database. This site does not provide investment advice.